Mitochondrial Proteolysis and Metabolic Control

Total Page:16

File Type:pdf, Size:1020Kb

Mitochondrial Proteolysis and Metabolic Control Downloaded from http://cshperspectives.cshlp.org/ on September 24, 2021 - Published by Cold Spring Harbor Laboratory Press Mitochondrial Proteolysis and Metabolic Control Sofia Ahola, Thomas Langer, and Thomas MacVicar Department of Mitochondrial Proteostasis, Max Planck Institute for Biology of Ageing, 50931 Cologne, Germany Correspondence: [email protected] Mitochondria are metabolic hubs that use multiple proteases to maintain proteostasis and to preserve their overall quality. A decline of mitochondrial proteolysis promotes cellular stress and may contribute to the aging process. Mitochondrial proteases have also emerged as tightly regulated enzymes required to support the remarkable mitochondrial plasticity nec- essary for metabolic adaptation in a number of physiological scenarios. Indeed, the mutation and dysfunction of several mitochondrial proteases can cause specific human diseases with severe metabolic phenotypes. Here, we present an overview of the proteolytic regulation of key mitochondrial functions such as respiration, lipid biosynthesis, and mitochondrial dy- namics, all of which are required for metabolic control. We also pay attention to how mito- chondrial proteases are acutely regulated in response to cellular stressors or changes in growth conditions, a greater understanding of which may one day uncover their therapeutic potential. ore than a billion years of evolution inner mitochondrial membrane (IMM), which Msince their fateful endosymbiotic origin is separated from the cytosol by the intermem- have directed mitochondria to play central brane space (IMS) and outer mitochondrial roles in metabolism and other cellular functions. membrane (OMM). Proteostasis in each sub- For instance, precise regulation of mitochondri- compartment is maintained by a number of al function is required for the production of mitochondrial proteases (mitoproteases) that ATP by oxidative phosphorylation (OXPHOS), promote protein quality control by degrading the maintenance of calcium homeostasis, and misfolded proteins and by processing newly im- programmed cell death. Only 13 mitochondrial ported proteins to facilitate their biogenesis proteins (∼1% of the total mitochondrial prote- (Quiros et al. 2015). Mitochondrial proteolysis ome) are encoded by resident mitochondrial is therefore a frontline mitochondrial quality- DNA (mtDNA) with the remainder originating control mechanism that combines with others, from the nucleus. These proteins are synthe- including reactive oxygen species (ROS) scav- sized on cytosolic ribosomes and directed to enging and mitophagy, to maintain overall mi- four distinct submitochondrial compartments tochondrial fitness. that are defined by the organelle’s unique double Acting as quality-control enzymes, all mito- membrane-bound structure. The mitochondrial proteases are likely to impact metabolism be- matrix is surrounded by the cristae-forming cause mitochondria represent a core metabolic Editors: Richard I. Morimoto, F. Ulrich Hartl, and Jeffery W. Kelly Additional Perspectives on Protein Homeostasis available at www.cshperspectives.org Copyright © 2019 Cold Spring Harbor Laboratory Press; all rights reserved Advanced Online Article. Cite this article as Cold Spring Harb Perspect Biol doi: 10.1101/cshperspect.a033936 1 Downloaded from http://cshperspectives.cshlp.org/ on September 24, 2021 - Published by Cold Spring Harbor Laboratory Press S. Ahola et al. hub. Nevertheless, recent advancements have prised of the peptidase PMCB and its noncata- demanded that we look beyond this classical lytic homolog PMCA (Mossmann et al. 2012). A description of mitoproteases. It is now clear matrix soluble complex, MPP processes the pos- that mitochondrial proteolysis offers a valuable itively charged presequence of the vast majority node for the regulation of specific mitochondrial of newly imported proteins destined for the functions and can be modulated by an array of matrix, IMM or IMS. Discarded presequence signaling inputs. Consequently, dysfunctional peptides are targeted by proteases within mito- mitoproteases contribute to a plethora of hu- chondria, such as Cym1 and Ste23 in yeast or man diseases, including cancer and neurode- PreP in humans, to be rapidly degraded and to generation and are strongly associated with the prevent their potentially toxic accumulation aging process. The loss of mitoprotease function (Stahl et al. 2002; Kambacheld et al. 2005; Fal- in these diseases impairs mitochondrial func- kevall et al. 2006; Mossmann et al. 2014; Taskin tion and causes metabolic-associated pheno- et al. 2017). types. In this review, we will focus on the close Mitoproteases mediating the processing of and often reciprocal relationship between mito- newly imported proteins often affect the subse- proteases and metabolic control. We will high- quent sorting of those proteins within mito- light the impact of mitoproteases on pathogen- chondria. For example, the inner mitochondrial esis and health span, a greater understanding of membrane peptidases (IMMPs) release soluble which may one day propel these enzymes for- proteins into the IMS by cleaving off their ward as therapeutic targets. hydrophobic sorting signals. The regulation of protein import and sorting by proteolysis there- fore has a huge impact on mitochondrial metab- PROTEOLYSIS ORGANIZES THE olism, for instance by ensuring the assembly of MITOCHONDRIAL PROTEOME OXPHOS complexes to drive the generation of Mitochondria contain at least 20 intrinsic and ATP. Consequently, mutations in MPPs cause a catalytically functional proteases, which are di- number of diseases in humans, with neurode- vided into three catalytic classes: 12 metallopro- generative disorders being the most prevalent. teases, seven Ser proteases, and one Cys protease Mutation of either MPP subunit gene, PMPCA (Quiros et al. 2015). The intrinsic mitoproteases or PMPCB, causes similar early-onset neurolog- are distributed between the submitochondrial ical phenotypes in patients, with the cerebellum compartments in which they contribute to mi- being particularly affected (Jobling et al. 2015; tochondrial function and homeostasis by cleav- Choquet et al. 2016; Joshi et al. 2016; Vogtle et al. ing or completely degrading target substrates. A 2018). Mutations within PMPCB appear to pro- common feature of mitoproteases is their pleio- duce more severe symptoms, perhaps because tropic nature, which arises from the fact that a mutation of the catalytic subunit disturbs MPP protease may have multiple diverse substrates. processing activity to the greater extent (Vogtle The best examples of multisubstrate mitopro- et al. 2018). Furthermore, and to highlight the teases are those that regulate mitochondrial pro- range of diseases caused by processing peptidase tein import and biogenesis. defects, mutation of IMMP subunit 2–like pro- Newly synthesised mitochondrial proteins tease (IMMP2) is associated with developmental must be imported and sorted to the correct disorders such as Tourette syndrome, whereas mitochondrial subcompartment. The majority mutation of MIPEP, encoding the mitochondri- of these proteins contain an amino-terminal al intermediate peptidase (MIP/Oct1), causes targeting signal, or presequence, which can be infant heart failure (Petek et al. 2001; Bertelsen cleaved by a number of processing peptidases et al. 2014; Eldomery et al. 2016). Specific dis- located in the matrix or IMM. Arguably the eases associated with mitochondrial dysfunc- most common example is the essential and tion (broadly termed as mitochondriopathies) conserved mitochondrial-processing peptidase are also triggered by mutations in the pre- (MPP) complex, which is a heterodimer com- sequences of mitochondrial proteins. For exam- 2 Advanced Online Article. Cite this article as Cold Spring Harb Perspect Biol doi: 10.1101/cshperspect.a033936 Downloaded from http://cshperspectives.cshlp.org/ on September 24, 2021 - Published by Cold Spring Harbor Laboratory Press Mitochondrial Proteolysis and Metabolic Control ple, impaired MPP processing of mutant Fra- tions that directly impact mitochondrial and taxin leads to disturbed iron homeostasis and cellular metabolic pathways. the neurodegenerative disorder Friedreich’s ataxia (Gakh et al. 2002), and a homozygous PROTEOLYTIC CONTROL OF mutation at the MPP-processing site of the pro- MITOCHONDRIAL RESPIRATION tease YME1L was recently found to impair mat- uration and destabilize the protein resulting in The production of ATP by OXPHOS can be neuropathy and optic atrophy (Hartmann et al. modulated by regulating the activities of meta- 2016). bolic enzymes, including the assembly of the Proteases can also modulate mitochondrial respiratory chain, the uptake of mitochondrial protein import by regulating components of the respiratory substrates, or by altering overall mi- import machinery. For instance, carboxy-termi- tochondrial mass. Nuclear and mitochondrial nal processing of the transmembrane protein gene expression and protein synthesis machin- Mgr2 by Imp (yeast IMMP) is required for ery must be synchronized and synergized to al- proper assembly and stabilization of the trans- low the synthesis and assembly of functional locase of inner mitochondrial membrane 23 OXPHOS complexes. Their coordination allows (Tim23/TIMM23) complex (Ieva et al. 2013). mitochondria to respond to ever-changing cel- Curiously, in comparison to yeast and fungal lular energy demands and substrate availability. Mgr2, the mammalian homolog ROMO1, Mitochondrial biogenesis, the maintenance of
Recommended publications
  • (12) United States Patent (10) Patent No.: US 6,395,889 B1 Robison (45) Date of Patent: May 28, 2002
    USOO6395889B1 (12) United States Patent (10) Patent No.: US 6,395,889 B1 Robison (45) Date of Patent: May 28, 2002 (54) NUCLEIC ACID MOLECULES ENCODING WO WO-98/56804 A1 * 12/1998 ........... CO7H/21/02 HUMAN PROTEASE HOMOLOGS WO WO-99/0785.0 A1 * 2/1999 ... C12N/15/12 WO WO-99/37660 A1 * 7/1999 ........... CO7H/21/04 (75) Inventor: fish E. Robison, Wilmington, MA OTHER PUBLICATIONS Vazquez, F., et al., 1999, “METH-1, a human ortholog of (73) Assignee: Millennium Pharmaceuticals, Inc., ADAMTS-1, and METH-2 are members of a new family of Cambridge, MA (US) proteins with angio-inhibitory activity', The Journal of c: - 0 Biological Chemistry, vol. 274, No. 33, pp. 23349–23357.* (*) Notice: Subject to any disclaimer, the term of this Descriptors of Protease Classes in Prosite and Pfam Data patent is extended or adjusted under 35 bases. U.S.C. 154(b) by 0 days. * cited by examiner (21) Appl. No.: 09/392, 184 Primary Examiner Ponnathapu Achutamurthy (22) Filed: Sep. 9, 1999 ASSistant Examiner William W. Moore (51) Int. Cl." C12N 15/57; C12N 15/12; (74) Attorney, Agent, or Firm-Alston & Bird LLP C12N 9/64; C12N 15/79 (57) ABSTRACT (52) U.S. Cl. .................... 536/23.2; 536/23.5; 435/69.1; 435/252.3; 435/320.1 The invention relates to polynucleotides encoding newly (58) Field of Search ............................... 536,232,235. identified protease homologs. The invention also relates to 435/6, 226, 69.1, 252.3 the proteases. The invention further relates to methods using s s s/ - - -us the protease polypeptides and polynucleotides as a target for (56) References Cited diagnosis and treatment in protease-mediated disorders.
    [Show full text]
  • Serine Proteases with Altered Sensitivity to Activity-Modulating
    (19) & (11) EP 2 045 321 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 08.04.2009 Bulletin 2009/15 C12N 9/00 (2006.01) C12N 15/00 (2006.01) C12Q 1/37 (2006.01) (21) Application number: 09150549.5 (22) Date of filing: 26.05.2006 (84) Designated Contracting States: • Haupts, Ulrich AT BE BG CH CY CZ DE DK EE ES FI FR GB GR 51519 Odenthal (DE) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • Coco, Wayne SK TR 50737 Köln (DE) •Tebbe, Jan (30) Priority: 27.05.2005 EP 05104543 50733 Köln (DE) • Votsmeier, Christian (62) Document number(s) of the earlier application(s) in 50259 Pulheim (DE) accordance with Art. 76 EPC: • Scheidig, Andreas 06763303.2 / 1 883 696 50823 Köln (DE) (71) Applicant: Direvo Biotech AG (74) Representative: von Kreisler Selting Werner 50829 Köln (DE) Patentanwälte P.O. Box 10 22 41 (72) Inventors: 50462 Köln (DE) • Koltermann, André 82057 Icking (DE) Remarks: • Kettling, Ulrich This application was filed on 14-01-2009 as a 81477 München (DE) divisional application to the application mentioned under INID code 62. (54) Serine proteases with altered sensitivity to activity-modulating substances (57) The present invention provides variants of ser- screening of the library in the presence of one or several ine proteases of the S1 class with altered sensitivity to activity-modulating substances, selection of variants with one or more activity-modulating substances. A method altered sensitivity to one or several activity-modulating for the generation of such proteases is disclosed, com- substances and isolation of those polynucleotide se- prising the provision of a protease library encoding poly- quences that encode for the selected variants.
    [Show full text]
  • Stress-Triggered Activation of the Metalloprotease Oma1 Involves Its
    University of Nebraska - Lincoln DigitalCommons@University of Nebraska - Lincoln Biochemistry -- Faculty Publications Biochemistry, Department of 2014 Stress-triggered Activation of the Metalloprotease Oma1 Involves Its C-terminal Region and Is Important for Mitochondrial Stress Protection in Yeast Iryna Bohovych University of Nebraska- Lincoln, [email protected] Garrett onD aldson University of Nebraska- Lincoln Sara Christianson University of Nebraska-Lincoln Nataliya Zahayko University of Nebraska-Lincoln Oleh Khalimonchuk University of Nebraska-Lincoln, [email protected] Follow this and additional works at: http://digitalcommons.unl.edu/biochemfacpub Part of the Biochemistry Commons, Biotechnology Commons, and the Other Biochemistry, Biophysics, and Structural Biology Commons Bohovych, Iryna; Donaldson, Garrett; Christianson, Sara; Zahayko, Nataliya; and Khalimonchuk, Oleh, "Stress-triggered Activation of the Metalloprotease Oma1 Involves Its C-terminal Region and Is Important for Mitochondrial Stress Protection in Yeast" (2014). Biochemistry -- Faculty Publications. 167. http://digitalcommons.unl.edu/biochemfacpub/167 This Article is brought to you for free and open access by the Biochemistry, Department of at DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Biochemistry -- Faculty Publications by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln. THE JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 289, NO. 19, pp. 13259–13272, May 9, 2014 © 2014 by The American Society
    [Show full text]
  • Role of PITRM1 in Mitochondrial Dysfunction and Neurodegeneration
    biomedicines Review Role of PITRM1 in Mitochondrial Dysfunction and Neurodegeneration Dario Brunetti 1,2 , Alessia Catania 2, Carlo Viscomi 3, Michela Deleidi 4, Laurence A. Bindoff 5,6, Daniele Ghezzi 2,7,* and Massimo Zeviani 8,9,* 1 Department of Medical Biotechnology and Translational Medicine, University of Milan, 20129 Milan, Italy; [email protected] 2 Unit of Medical Genetics and Neurogenetics, Fondazione IRCCS Istituto Neurologico Carlo Besta, 20126 Milan, Italy; [email protected] 3 Department of Biomedical Sciences, University of Padova, 35131 Padova, Italy; [email protected] 4 German Center for Neurodegenerative Diseases (DZNE), 72076 Tübingen, Germany; [email protected] 5 Neuro-SysMed, Center of Excellence for Clinical Research in Neurological Diseases, Haukeland University Hospital, N-5021 Bergen, Norway; [email protected] 6 Department of Clinical Medicine, University of Bergen, N-5021 Bergen, Norway 7 Department of Pathophysiology and Transplantation, University of Milan, 20122 Milan, Italy 8 Department of Neurosciences, University of Padova, 35128 Padova, Italy 9 Venetian Institute of Molecular Medicine, 35128 Padova, Italy * Correspondence: [email protected] (D.G.); [email protected] (M.Z.) Abstract: Mounting evidence shows a link between mitochondrial dysfunction and neurodegenera- tive disorders, including Alzheimer Disease. Increased oxidative stress, defective mitodynamics, and impaired oxidative phosphorylation leading to decreased ATP production, can determine synaptic dysfunction, apoptosis, and neurodegeneration. Furthermore, mitochondrial proteostasis and the Citation: Brunetti, D.; Catania, A.; protease-mediated quality control system, carrying out degradation of potentially toxic peptides Viscomi, C.; Deleidi, M.; Bindoff, L.A.; and misfolded or damaged proteins inside mitochondria, are emerging as potential pathogenetic Ghezzi, D.; Zeviani, M.
    [Show full text]
  • Handbook of Proteolytic Enzymes Second Edition Volume 1 Aspartic and Metallo Peptidases
    Handbook of Proteolytic Enzymes Second Edition Volume 1 Aspartic and Metallo Peptidases Alan J. Barrett Neil D. Rawlings J. Fred Woessner Editor biographies xxi Contributors xxiii Preface xxxi Introduction ' Abbreviations xxxvii ASPARTIC PEPTIDASES Introduction 1 Aspartic peptidases and their clans 3 2 Catalytic pathway of aspartic peptidases 12 Clan AA Family Al 3 Pepsin A 19 4 Pepsin B 28 5 Chymosin 29 6 Cathepsin E 33 7 Gastricsin 38 8 Cathepsin D 43 9 Napsin A 52 10 Renin 54 11 Mouse submandibular renin 62 12 Memapsin 1 64 13 Memapsin 2 66 14 Plasmepsins 70 15 Plasmepsin II 73 16 Tick heme-binding aspartic proteinase 76 17 Phytepsin 77 18 Nepenthesin 85 19 Saccharopepsin 87 20 Neurosporapepsin 90 21 Acrocylindropepsin 9 1 22 Aspergillopepsin I 92 23 Penicillopepsin 99 24 Endothiapepsin 104 25 Rhizopuspepsin 108 26 Mucorpepsin 11 1 27 Polyporopepsin 113 28 Candidapepsin 115 29 Candiparapsin 120 30 Canditropsin 123 31 Syncephapepsin 125 32 Barrierpepsin 126 33 Yapsin 1 128 34 Yapsin 2 132 35 Yapsin A 133 36 Pregnancy-associated glycoproteins 135 37 Pepsin F 137 38 Rhodotorulapepsin 139 39 Cladosporopepsin 140 40 Pycnoporopepsin 141 Family A2 and others 41 Human immunodeficiency virus 1 retropepsin 144 42 Human immunodeficiency virus 2 retropepsin 154 43 Simian immunodeficiency virus retropepsin 158 44 Equine infectious anemia virus retropepsin 160 45 Rous sarcoma virus retropepsin and avian myeloblastosis virus retropepsin 163 46 Human T-cell leukemia virus type I (HTLV-I) retropepsin 166 47 Bovine leukemia virus retropepsin 169 48
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2004/0081648A1 Afeyan Et Al
    US 2004.008 1648A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0081648A1 Afeyan et al. (43) Pub. Date: Apr. 29, 2004 (54) ADZYMES AND USES THEREOF Publication Classification (76) Inventors: Noubar B. Afeyan, Lexington, MA (51) Int. Cl." ............................. A61K 38/48; C12N 9/64 (US); Frank D. Lee, Chestnut Hill, MA (52) U.S. Cl. ......................................... 424/94.63; 435/226 (US); Gordon G. Wong, Brookline, MA (US); Ruchira Das Gupta, Auburndale, MA (US); Brian Baynes, (57) ABSTRACT Somerville, MA (US) Disclosed is a family of novel protein constructs, useful as Correspondence Address: drugs and for other purposes, termed “adzymes, comprising ROPES & GRAY LLP an address moiety and a catalytic domain. In Some types of disclosed adzymes, the address binds with a binding site on ONE INTERNATIONAL PLACE or in functional proximity to a targeted biomolecule, e.g., an BOSTON, MA 02110-2624 (US) extracellular targeted biomolecule, and is disposed adjacent (21) Appl. No.: 10/650,592 the catalytic domain So that its affinity Serves to confer a new Specificity to the catalytic domain by increasing the effective (22) Filed: Aug. 27, 2003 local concentration of the target in the vicinity of the catalytic domain. The present invention also provides phar Related U.S. Application Data maceutical compositions comprising these adzymes, meth ods of making adzymes, DNA's encoding adzymes or parts (60) Provisional application No. 60/406,517, filed on Aug. thereof, and methods of using adzymes, Such as for treating 27, 2002. Provisional application No. 60/423,754, human Subjects Suffering from a disease, Such as a disease filed on Nov.
    [Show full text]
  • 12) United States Patent (10
    US007635572B2 (12) UnitedO States Patent (10) Patent No.: US 7,635,572 B2 Zhou et al. (45) Date of Patent: Dec. 22, 2009 (54) METHODS FOR CONDUCTING ASSAYS FOR 5,506,121 A 4/1996 Skerra et al. ENZYME ACTIVITY ON PROTEIN 5,510,270 A 4/1996 Fodor et al. MICROARRAYS 5,512,492 A 4/1996 Herron et al. 5,516,635 A 5/1996 Ekins et al. (75) Inventors: Fang X. Zhou, New Haven, CT (US); 5,532,128 A 7/1996 Eggers Barry Schweitzer, Cheshire, CT (US) 5,538,897 A 7/1996 Yates, III et al. s s 5,541,070 A 7/1996 Kauvar (73) Assignee: Life Technologies Corporation, .. S.E. al Carlsbad, CA (US) 5,585,069 A 12/1996 Zanzucchi et al. 5,585,639 A 12/1996 Dorsel et al. (*) Notice: Subject to any disclaimer, the term of this 5,593,838 A 1/1997 Zanzucchi et al. patent is extended or adjusted under 35 5,605,662 A 2f1997 Heller et al. U.S.C. 154(b) by 0 days. 5,620,850 A 4/1997 Bamdad et al. 5,624,711 A 4/1997 Sundberg et al. (21) Appl. No.: 10/865,431 5,627,369 A 5/1997 Vestal et al. 5,629,213 A 5/1997 Kornguth et al. (22) Filed: Jun. 9, 2004 (Continued) (65) Prior Publication Data FOREIGN PATENT DOCUMENTS US 2005/O118665 A1 Jun. 2, 2005 EP 596421 10, 1993 EP 0619321 12/1994 (51) Int. Cl. EP O664452 7, 1995 CI2O 1/50 (2006.01) EP O818467 1, 1998 (52) U.S.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2012/0266329 A1 Mathur Et Al
    US 2012026.6329A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0266329 A1 Mathur et al. (43) Pub. Date: Oct. 18, 2012 (54) NUCLEICACIDS AND PROTEINS AND CI2N 9/10 (2006.01) METHODS FOR MAKING AND USING THEMI CI2N 9/24 (2006.01) CI2N 9/02 (2006.01) (75) Inventors: Eric J. Mathur, Carlsbad, CA CI2N 9/06 (2006.01) (US); Cathy Chang, San Marcos, CI2P 2L/02 (2006.01) CA (US) CI2O I/04 (2006.01) CI2N 9/96 (2006.01) (73) Assignee: BP Corporation North America CI2N 5/82 (2006.01) Inc., Houston, TX (US) CI2N 15/53 (2006.01) CI2N IS/54 (2006.01) CI2N 15/57 2006.O1 (22) Filed: Feb. 20, 2012 CI2N IS/60 308: Related U.S. Application Data EN f :08: (62) Division of application No. 1 1/817,403, filed on May AOIH 5/00 (2006.01) 7, 2008, now Pat. No. 8,119,385, filed as application AOIH 5/10 (2006.01) No. PCT/US2006/007642 on Mar. 3, 2006. C07K I4/00 (2006.01) CI2N IS/II (2006.01) (60) Provisional application No. 60/658,984, filed on Mar. AOIH I/06 (2006.01) 4, 2005. CI2N 15/63 (2006.01) Publication Classification (52) U.S. Cl. ................... 800/293; 435/320.1; 435/252.3: 435/325; 435/254.11: 435/254.2:435/348; (51) Int. Cl. 435/419; 435/195; 435/196; 435/198: 435/233; CI2N 15/52 (2006.01) 435/201:435/232; 435/208; 435/227; 435/193; CI2N 15/85 (2006.01) 435/200; 435/189: 435/191: 435/69.1; 435/34; CI2N 5/86 (2006.01) 435/188:536/23.2; 435/468; 800/298; 800/320; CI2N 15/867 (2006.01) 800/317.2: 800/317.4: 800/320.3: 800/306; CI2N 5/864 (2006.01) 800/312 800/320.2: 800/317.3; 800/322; CI2N 5/8 (2006.01) 800/320.1; 530/350, 536/23.1: 800/278; 800/294 CI2N I/2 (2006.01) CI2N 5/10 (2006.01) (57) ABSTRACT CI2N L/15 (2006.01) CI2N I/19 (2006.01) The invention provides polypeptides, including enzymes, CI2N 9/14 (2006.01) structural proteins and binding proteins, polynucleotides CI2N 9/16 (2006.01) encoding these polypeptides, and methods of making and CI2N 9/20 (2006.01) using these polynucleotides and polypeptides.
    [Show full text]
  • Identification of a Metallopeptidase with TOP-Like Activity in Paracoccidioides Brasiliensis, with Increased Expression in A
    Medical Mycology January 2012, 50, 81–90 Identifi cation of a metallopeptidase with TOP-like activity in Paracoccidioides brasiliensis, with increased expression in a virulent strain ELLEN T. GRAVI * , THAYSA PASCHOALIN * , BIANCA R. DIAS * , DAYSON F. MOREIRA ‡ , JOS É E. BELIZARIO ‡ , VITOR OLIVEIRA † , ADRIANA K. CARMONA † , MARIA A. JULIANO † , LUIZ R. TRAVASSOS * & ELAINE G. RODRIGUES * * Unidade de Oncologia Experimental (UNONEX), Departamento de Microbiologia, Imunologia e Parasitologia, and Downloaded from https://academic.oup.com/mmy/article/50/1/81/989549 by guest on 30 September 2021 † Departamento de Biof í sica, Universidade Federal de S ã o Paulo-Escola Paulista de Medicina (UNIFESP-EPM), Brazil, and ‡ Departamento de Farmacologia, Universidade de S ã o Paulo (USP), Brazil Paracoccidioidomycosis (PCM), caused by the pathogenic fungus Paracoccidioides brasiliensis , is a systemic mycosis with severe acute and chronic forms. The pathology of PCM is not completely understood, and the role of proteases in the infection is not clearly defi ned. In this report, we describe a metallopeptidase activity in P. brasiliensis total and cytosolic protein extracts similar to that of mammalian thimet oligopeptidase (TOP). The analogous enzyme was suggested by analysis of P. brasiliensis genome data- bank and by hydrolytic activity of the FRET peptide Abz-GFSPFRQ-EDDnp which was completely inhibited by o -phenanthrolin and signifi cantly inhibited by the TOP inhibitor, JA-2. This activity was also partially inhibited by IgG purifi ed from patients with PCM, but not from normal individuals. As shown by high-performance liquid chromatography (HPLC), the hydrolysis of bradykinin had the same pattern as that of mammalian TOP, and anti-mammalian TOP antibodies signifi cantly inhibited fungal cytosolic peptidase activity.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2011/0044968 A1 Bolotin Et Al
    US 20110044968A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0044968 A1 Bolotin et al. (43) Pub. Date: Feb. 24, 2011 (54) COMPOSITIONS FOR TREATMENT WITH (86). PCT No.: PCT/USO9A36648 METALLOPEPTIDASES, METHODS OF MAKING AND USING THE SAME S371 (c)(1), (2), (4) Date: Nov. 5, 2010 (75) Inventors: Elijah M. Bolotin, Bothell, WA Related U.S. Application Data WA(US); (US); Gerardo Penelope Castillo, Markham, Bothell, (60) Fyal application No. 61/068.896, filed on Mar. Clifton, VA (US); Manshun Lai, s Bothell, WA (US) Publication Classification (51) Int. Cl. Correspondence Address: A638/54 (2006.01) WILSON SONSIN GOODRCH AND ROSAT f CI2N 9/96 (2006.01) PHARMAN LTD A6IP3L/00 (2006.01) 650 PAGE MILL ROAD A6IP 25/28 (2006.01) PALO ALTO, CA 94.304 (US) (52) U.S. Cl. ........................................ 424/94.3; 435/188 (57) ABSTRACT (73)73) AssigneeAssi : WPh re NC orporation,tion. SeattlSealue, The present invention is directed to biocompatible composi tions and the use of metal bridges to connect a back-bone and a metallopeptidase active agent. In certain instances, the Sub (21) Appl. No.: 12/921,670 ject compositions provide a means of achieving Sustained release of the metallopeptidase active agent after administra (22) PCT Filed: Mar. 10, 2009 tion to a subject. Patent Application Publication Feb. 24, 2011 Sheet 1 of 13 US 2011/0044968 A1 Figure 1 (1) Polymeric Backbone (branched or unbranched) 2) Chelating moieties (3) Metalions ( 4) Protective chains (5) Metallopeptidase active agent Patent Application Publication Feb. 24, 2011 Sheet 2 of 13 US 2011/0044968 A1 Figure 2 O 120% poss C D 100% O 80% w 60% s CD 20% n S PGC-NTA-Zn PGC-NTA Lysostaphin Lysostaphin Patent Application Publication Feb.
    [Show full text]
  • Supporting Information
    Supporting Information © Copyright Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, 2007 © Copyright Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, 2007 Supporting Information for Identification of Protein Fold Topology Shared between Different Folds Inhibited by Natural Products Bernadette M. McArdle, Ronald J. Quinn* Table S-1 Result of data-mining for natural product inhibitors of the Zincin-like fold [a] NP/derivative NP type/ mode Inhibits Potency PDB Fold Doesn’t Inhibit Fold [41, [41] [44] [44] [45] actinonin peptide deformylase Ki = 0.28 nM 1q1y 1ix1 Peptide ACE Zincin-like 42] [41] [45] IC50 = 0.8 nM 1g2a deformylase (IC50 > 100 µM) [42] [46] Ki = 0.3 nM 1lqw [46] Ki = 0.012 -0.025 1lqy µM[43] 1lru[46] aminopeptidase P Creatinase/ 1lry[46] (3.4.11.9)[101] aminopeptidase Kis = 0.135 µM[94] no pdb glutamyl ?homology with meprin A Kii = 1.57 µM[94] ?Zincin-like aminopeptidase TET (homology with (3.4.11.7)[96] astacin) Kis = 130 µM[94] aminopeptidase W ?no pdb astacin Kii = 9500 µM[94] Zincin-like (3.4.11.16)[96] no sequence [95] IC50 = 25 nM no pdb aminopeptidase A ? [96] alanyl aminopeptidase IC50 = 2 µM ?Zincin-like (?EC) [87-91] [97] [97] (N/M) (3.4.11.2) IC50 = 0.4 µg/mL (homology with IC50 >100µg/mL LTA4H) [98] Ki = 1.4 mM arginine [99] human neutrophil IC50 = 0.3 µM Zincin-like aminopeptidase (B) ?Zincin-like [97] collagenase (MMP-8) (3.4.11.6) IC 50 > (homology with [99] IC50 = 0.19 µM 100 µg/mL LTA4H) [45] collagenase IC50 = 1 µM Zincin-like (MMP-1) [99] IC50 = 0.33 µM gelatinase B Zincin-like (MMP-9) [99] IC50 = 1.7
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2015/0240226A1 Mathur Et Al
    US 20150240226A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2015/0240226A1 Mathur et al. (43) Pub. Date: Aug. 27, 2015 (54) NUCLEICACIDS AND PROTEINS AND CI2N 9/16 (2006.01) METHODS FOR MAKING AND USING THEMI CI2N 9/02 (2006.01) CI2N 9/78 (2006.01) (71) Applicant: BP Corporation North America Inc., CI2N 9/12 (2006.01) Naperville, IL (US) CI2N 9/24 (2006.01) CI2O 1/02 (2006.01) (72) Inventors: Eric J. Mathur, San Diego, CA (US); CI2N 9/42 (2006.01) Cathy Chang, San Marcos, CA (US) (52) U.S. Cl. CPC. CI2N 9/88 (2013.01); C12O 1/02 (2013.01); (21) Appl. No.: 14/630,006 CI2O I/04 (2013.01): CI2N 9/80 (2013.01); CI2N 9/241.1 (2013.01); C12N 9/0065 (22) Filed: Feb. 24, 2015 (2013.01); C12N 9/2437 (2013.01); C12N 9/14 Related U.S. Application Data (2013.01); C12N 9/16 (2013.01); C12N 9/0061 (2013.01); C12N 9/78 (2013.01); C12N 9/0071 (62) Division of application No. 13/400,365, filed on Feb. (2013.01); C12N 9/1241 (2013.01): CI2N 20, 2012, now Pat. No. 8,962,800, which is a division 9/2482 (2013.01); C07K 2/00 (2013.01); C12Y of application No. 1 1/817,403, filed on May 7, 2008, 305/01004 (2013.01); C12Y 1 1 1/01016 now Pat. No. 8,119,385, filed as application No. PCT/ (2013.01); C12Y302/01004 (2013.01); C12Y US2006/007642 on Mar. 3, 2006.
    [Show full text]